top of page

Pioneering a disruptive
therapeutic modality

Transformative medicines for
Deubiquitination Therapeutics

Our Approach

Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. We are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drugging targets by establishing a powerful small-molecule modality for a wide variety of devastating diseases.

The big idea

LIGHTBULB.png

Aberrant ubiquitination is a driver of disease.

This could be due to a number of reasons:

  • Excessive protein degradation

  • Localization of proteins in the “wrong” compartment

  • Pathway activation through primary ubiquitination step

Targeted deubiquitination can be beneficial to address these issues and restore normal function.

The challenge

thechallenge_icon.png

123-456-7890

Drugging a universal post translational
signal – ubiquitin – in a target-specific manner

The solution

thesolution_icon.png

Find us on Facebook

Establishing an adaptable platform
for restoring protein stability and normal function

our approach

Reduced protein expression and aberrant activation of cell growth and immune signaling cascades are common underlying drivers of disease. Genetic mutations can reduce the stability of proteins with essential function; tumor cells often eliminate key regulatory factors to grow unchecked; pathogens co-opt the host ubiquitin-proteasome system (UPS) to modulate immune response. Ubiquitin is the master regulator of protein lifecycle and activity, involved in both protein degradation and protein activation and signaling. Deubiquitinases (DUBs) are nature’s ubiquitin editors, involved in broad biological activities, and have emerged as a highly sought-after therapeutic target. 

Our Approach

At Stablix, we are establishing a new paradigm for tackling diverse diseases by harnessing the power of the body’s own cellular machinery. We generate heterobifunctional small molecules that selectively recruit active deubiquitinases (DUBs) to target proteins to precisely remove ubiquitin. Targeting proteins subject to aberrant ubiquitination restores deficient proteins to therapeutic levels  alternatively restores normal function. We are leveraging targeted deubiquitination to develop programs to treat cancer, rare diseases and immunological disorders.

our platform
our team

Who We Are

Stablix, co-located at sites in New York City and Boston, is a preclinical stage biotechnology company, pioneering small molecule medicines for targeted deubiquitination therapeutics. We are an experienced, multi-disciplinary team with a combined power of industry knowledge and creative talent.

Leadership

tony (3) (1).png

Tony Kingsley
CEO

 

eddine-saiah.jpg

Eddine Saiah, PhD
CSO

DSC03773_edited.jpg

Scott Kanner, PhD
Associate Director 
Platform Sciences 
Co-Founder

Scientific Advisors

hcolecraft_edited.jpg

Henry Colecraft, PhD
Chair of SAB

Co-Founder

BMK%20Head%20Shot%202021_edited.jpg

Benedikt Kessler, PhD
University of Oxford
Professor

chris_dinsmore_edited_edited.jpg

Chris Dinsmore, PhD
CSO Kronos Bio

andrew_turnbull_headshot_edited.jpg

Andrew Turnbull, PhD
Senior Principal Scientist
CRUK-TDL

Board of Directors 

Carlo_edited.jpg

Carlo Rizzuto, PhD
Director

Rami_Headshot.jpg

Rami Hannoush, PhD
Director

Ali.jpeg

Ali Behbahani, MD
Director

tony (3) (1).png

Tony Kingsley
Director

douglas-williams.jpg

Douglas Williams, PhD
Director

J. C. Lopez.jpg

J.C. Lopez, MD
Observer

bod-bihua-chen.jpg

Bihua Chen
Observer

bod-ezana-demissie.jpg

Ezana Demissie
Observer

Our Investors

VER_Logo_2c_Coated.png
NEA_logo.png
CAM%20Logo%20Blue_edited.png
Euclidean%20Capital%20logo_edited.png
ARE_Proprietary_Products_RGB_VentureInve
bottom of page